[ Inside the business ]

DXCM stock analysis

DXCM · Dexcom Inc

Surgical and medical instruments and apparatus. Growing 11%. Keeps 24¢ of every dollar.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 2.3× sales in 5 yrs. Evidence: sales +11% · 24¢ profit/$1.

01 What's priced in?2.3× sales in 5 yrs
Sales now$5.1B
Needed in 5 yrs$11.9B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Customer A: 55% of sales
Customer A 55%Customer C 46%Customer B 35%Everyone else
Prepaid $3MSales +11%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 24¢ per $1, rising
'21'22'23'24'2524¢
Before running costs: 65% → 60%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −2.4%/yrDebt $0
07 What could break it?1 to watch
  • Growth slowing

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +15%, +13%, then +11% vs. a year ago.

What could go wrong

Few warning signs.

It has moved 1.1× the market. In the 2008 crisis it fell 56% while the market fell 51%. Debt is covered by cash.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

24¢ profit.

37¢ to make what it sells, 39¢ on research and overhead, 24¢ left over. Revenue $5.1B in the last 12 months.

Its market

0.3× the economy.

The government expects its industry, fabricated metal product manufacturing, to grow 0.7% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Shake-out.

Its cash flows are mixed, typical of a company in transition.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 143¢ of each $1 of profit.

Competitive advantage

7 of 10 years.

Returns beat its 10.4% cost of capital in 7 of the last 10 years. Gross margin went from 66% to 60%.

Future bets

12% on research.

$608M a year on R&D. $316M on equipment and buildings.

All figures from Dexcom Inc's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.